Article
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Pharmacogenetics - 1 Feb 1996
Ratain M J, Mick R, Janisch L, Berezin F, Schilsky R L, Vogelzang N J, Kut M
Abstract excerpt
Amonafide is extensively metabolized, including conversion by N-acetylation to an active metabolite. Our previous studies have shown that fast acetylators of amonafide have increased toxicity, and we have recommended doses of 250 and 375 mg m-2 day-1 for 5 days, for fast and slow acetylators, respectively. Despite phenotype-specific dosing, significant variability in leukopenia persisted. The goal of this study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.